(NASDAQ: TLSI) Trisalus Life Sciences's forecast annual revenue growth rate of 35.31% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.42%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.06%.
Trisalus Life Sciences's revenue in 2026 is $44,883,000.On average, 7 Wall Street analysts forecast TLSI's revenue for 2026 to be $3,282,345,297, with the lowest TLSI revenue forecast at $2,925,146,729, and the highest TLSI revenue forecast at $3,487,722,190. On average, 8 Wall Street analysts forecast TLSI's revenue for 2027 to be $5,111,206,876, with the lowest TLSI revenue forecast at $4,219,193,121, and the highest TLSI revenue forecast at $5,920,922,473.
In 2028, TLSI is forecast to generate $6,828,904,527 in revenue, with the lowest revenue forecast at $5,820,199,356 and the highest revenue forecast at $7,631,004,474.